What is BJDX's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.00B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for BJDX?

P/E (TTM) is n/a and 52-week range is $0.76 to $15.12 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s BJDX figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for BJDX?

The company profile lists net income (TTM) near $-51M, EPS (TTM) near $-49.44 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Bluejay Diagnostics Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Acton, Massachusetts, US, 1M shares outstanding, ISIN US0956336087 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

Free AI scores & summaries library

Bluejay Diagnostics Inc

$BJDX

Health Care · Health Care Equipment & Supplies

IR Run Scenarios

$0.75

-3.36%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Bluejay Diagnostics, Inc. operates as a diagnostic company. The company is headquartered in Acton, Massachusetts and currently employs 6 full-time employees. The company went IPO on 2021-11-10. The company develops rapid tests using whole blood on its Symphony technology platform (Symphony), which consists of an analyzer and single-use protein detection cartridges that have the function of automatic stepwise feeding of reagent. The Symphony device is designed to produce laboratory-quality results in 20 minutes in critical care settings, including Intensive Care Units (ICUs) and Emergency Rooms (ERs). Its product candidate, the Symphony IL-6 test, is an immunoassay for the measurement of interleukin-6 (IL-6) to be used for the monitoring of disease progression in critical care settings. The company is focused on pursuing the Symphony IL-6 test in the context of sepsis. IL-6 is a clinically established inflammatory biomarker, and is considered a 'first-responder', for the assessment of severity of infection and inflammation across many disease indications, including sepsis.

Employees

Website

bluejaydx.com/

IPO

2021-11-10

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)